Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A myasthenia gravis detection kit and application using a combination of non-coding lnc-cxcl1 and coding gene cxcl1 as a detection or diagnostic screening marker

A myasthenia gravis, gene-encoding technology, applied in the biological field, can solve problems such as expression and biological functions that have not been reported

Active Publication Date: 2018-02-23
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The gene encoding cxcl1 is CXCR2 + Chemokine for family cells such as neutrophils; non-coding Lnc-CXCL1 is a non-expressed distinct transcript encoding cxcl1 whose expression and biological function have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A myasthenia gravis detection kit and application using a combination of non-coding lnc-cxcl1 and coding gene cxcl1 as a detection or diagnostic screening marker
  • A myasthenia gravis detection kit and application using a combination of non-coding lnc-cxcl1 and coding gene cxcl1 as a detection or diagnostic screening marker
  • A myasthenia gravis detection kit and application using a combination of non-coding lnc-cxcl1 and coding gene cxcl1 as a detection or diagnostic screening marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] The conventional reagents used in the examples are all commercially available, and the primer pairs described in the examples are as follows:

[0031] A. The specific PCR primer pair for real-time quantification of non-coding lnc-CXCL1 is as follows:

[0032] Forward primer: 5'-AGTCAGTGAGTCTCTCTCTTCCCT-3' (SEQ ID NO.1);

[0033] Reverse primer: 5'-CACCAGTGAGCTTCCTCCTC-3' (SEQ ID NO.2);

[0034] B. The specific PCR primer pair for real-time quantification of the coding gene cxcl1 is as follows:

[0035] Forward primer: 5'-GCGCGCAGCAGGAGCGT-3' (SEQ ID NO.3);

[0036] Reverse primer: 5'-CACCAGTGAGCTTCCTCCTC-3' (SEQ ID NO.4);

[0037] The real-time quantitative specific PCR primer pair of C, GAPDH is as follows:

[0038] Forward primer: 5'-GAGTCAACGGATTTGGTCGT-3' (SEQ ID NO.5);

[0039] Reverse primer: 5'-TTGATTTTGGAGGGATCTCG-3' (SEQ ID NO.6).

[0040] 1. RNA extraction method:

[0041] (1) Take 5ml of peripheral cubital vein blood sample with EDTA anticoagulant bloo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a myasthenia gravis detection reagent kit with the combination of non-coded lnc-CXCL1 and a coded gene cxcl1 as a detection or diagnosis screening marker and application. By detecting the expression levels of lnc-CXCL1 and the coded gene cxcl1 in peripheral blood specimens of patients suffering from myasthenia gravis in a relative quantification mode, the reagent kit achieves the effects of screening patients suffering from myasthenia gravis, carrying out QMG on clinical symptoms, and judging hormone therapy.

Description

technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to a myasthenia gravis detection kit and its application using the combination of non-coding lnc-CXCL1 and coding gene cxcl1 as detection or diagnostic screening markers. Background technique [0002] Myasthenia gravis (MG) is the most common autoimmune disease among neuromuscular junction-related diseases. Its typical clinical manifestations are fluctuating systemic skeletal muscle fatigue and weakness, including the involvement of respiratory muscles. Its prevalence in the world is about 40-180 / 1 million, and the annual incidence is about 4-12 / 1 million. In recent years, with the improvement of detection technology, new antibodies have been discovered continuously, and the incidence of MG On the rise, especially in late-onset MG. According to the different parts involved, the age of onset and the type of serum antibody, MG can be divided into different subtypes. Although ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883C12N15/11
CPCC12Q1/6837C12Q1/6883C12Q2600/158C12Q2600/178
Inventor 罗朝辉刘晓芳徐立群罗梦川杨欢肖波
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com